Cite
MLA Citation
David T Rubin et al.. “Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.” Lancet gastroenterology and hepatology, vol. 7, 2022, pp. 17–27. http://access.bl.uk/ark:/81055/vdc_100178520433.0x000001